TSR-042 in People With Locally Advanced Mismatch Repair Deficient Rectal Cancer
Conditions: Rectal Adenocarcinoma; Clinical Stage: Stage II (T3-4, N-); Stage III (Any T, N+) Interventions: Drug: TSR-042; Drug: capecitabine; Radiation: Intensity Modulated Radiation Therapy (IMRT) Sponsors: Memorial Sloan Kettering Cancer Center; Tesaro, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroschisis Repair | Intensity-Modulated Radiation Therapy | Radiation Therapy | Rectal Cancers | Research | Xeloda